Eisai Co., Ltd. ESALY
Set alert
61.51 0.00 0.00%
As of Jan 30, 3:59 PM ET
61.00 Day range 63.29
52-week range unavailable
- Open
- 62.35
- Prev close
- 61.51
- Mkt cap
- 17.64B
- Vol
- 331.86K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 61.00
- High
- 63.29
- Earnings
- Feb 2, 2023
Next earnings
Feb 2, 2023
Expected Feb 2, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 5, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Feb 3, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 1, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
News
- Eisai (OTCMKTS:ESALY) Stock Crosses Below 50 Day Moving Average – Time to Sell?
- Eisai (OTCMKTS:ESALY) Share Price Crosses Below 50 Day Moving Average – Here’s Why
- These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
- Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
- President Trump demands drugmakers slash prices within 60 days
- Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
- UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
- Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
- Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
- Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Your note
Sign in to keep a note on ESALY — it syncs with the Stock Master app.